Clinical Trial Update: Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial exploring camrelizumab with FOLFOX as neoadjuvant therapy for resectable gastric and gastroesophageal junctional adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• FOLFOX

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN